Coyle JT (2017) Schizophrenia: Basic and clinical. Adv Neurobiol 15:255–280

Article  PubMed  Google Scholar 

Zhu MH, Liu ZJ, Hu QY, Yang JY, Jin Y, Zhu N, Huang Y, Shi DH, Liu MJ, Tan HY, Zhao L, Lv QY, Yi ZH, Wu FC, Li ZZ (2022) Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 9:59

CAS  PubMed  PubMed Central  Google Scholar 

Lee SJ, Kim KR, Lee SY, An SK (2017) Impaired social and role function in ultra-high risk for psychosis and first-episode schizophrenia: Its relations with negative symptoms. Psychiatry Investig 14:539–545

Article  PubMed  PubMed Central  Google Scholar 

Kaneko K (2018) Negative symptoms and cognitive impairments in schizophrenia: Two key symptoms negatively influencing social functioning. Yonago Acta Med 61:91–102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pandurangi AK, Buckley PF (2020) Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia. Curr Top Behav Neurosci 44:227–244

Article  CAS  PubMed  Google Scholar 

Zhu S, Zhao L, Fan Y, Lv Q, Wu K, Lang X, Li Z, Yi Z, Geng D (2020) Interaction between TNF-alpha and oxidative stress status in first-episode drug-naive schizophrenia. Psychoneuroendocrinology 114:104595

Article  CAS  PubMed  Google Scholar 

Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S (2022) Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand 146:6–20

Article  PubMed  PubMed Central  Google Scholar 

Goldsmith DR, Haroon E, Miller AH, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Seidman L, Tsuang M, Woods SW, Walker EF, Perkins DO (2019) Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain Behav Immun 76:268–274

Article  CAS  PubMed  Google Scholar 

Goldsmith DR, Rapaport MH (2020) Inflammation and negative symptoms of schizophrenia: Implications for reward processing and motivational deficits. Front Psychiatry 11:46

Article  PubMed  PubMed Central  Google Scholar 

Limosin F (2014) Neurodevelopmental and environmental hypotheses of negative symptoms of schizophrenia. BMC Psychiatry 14:88

Article  PubMed  PubMed Central  Google Scholar 

Juchnowicz D, Dzikowski M, Rog J, Waszkiewicz N, Zalewska A, Maciejczyk M, Karakula-Juchnowicz H (2021) Oxidative stress biomarkers as a predictor of stage illness and clinical course of schizophrenia. Front Psychiatry 12:728986

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Blanco L, Garcia-Portilla MP, Garcia-Alvarez L, de la Fuente-Tomas L, Iglesias Garcia C, Saiz PA, Rodriguez-Gonzalez S, Coto-Montes A, Bobes J (2018) Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. Rev Psiquiatr Salud Ment (Engl Ed) 11:130–140

PubMed  Google Scholar 

Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S (2013) N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 36:185–192

Article  CAS  PubMed  Google Scholar 

Wu S, Gao Q, Zhao P, Gao Y, Xi Y, Wang X, Liang Y, Shi H, Ma Y (2016) Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice. Behav Brain Res 301:55–62

Article  CAS  PubMed  Google Scholar 

Hayes JD, Dinkova-Kostova AT (2014) The nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199–218

Article  CAS  PubMed  Google Scholar 

Esfandyari S, Aleyasin A, Noroozi Z, Taheri M, Khodarahmian M, Eslami M, Rashidi Z, Amidi F (2021) The protective effect of sulforaphane against oxidative stress through activation of nrf2/are pathway in human granulosa cells. Cell J 23:692–700

PubMed  PubMed Central  Google Scholar 

Rakariyatham K, Wu X, Tang Z, Han Y, Wang Q, Xiao H (2018) Synergism between luteolin and sulforaphane in anti-inflammation. Food Funct 9:5115–5123

Article  CAS  PubMed  Google Scholar 

Lopez-Chillon MT, Carazo-Diaz C, Prieto-Merino D, Zafrilla P, Moreno DA, Villano D (2019) Effects of long-term consumption of broccoli sprouts on inflammatory markers in overweight subjects. Clin Nutr 38:745–752

Article  CAS  PubMed  Google Scholar 

Leucht S (2014) Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 75(Suppl 1):8–14

Article  PubMed  Google Scholar 

Song X, Fan X, Li X, Zhang W, Gao J, Zhao J, Harrington A, Ziedonis D, Lv L (2014) Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia. Psychopharmacology 231:319–325

Article  CAS  PubMed  Google Scholar 

Noto MN, Maes M, Nunes SOV, Ota VK, Rossaneis AC, Verri WA Jr, Cordeiro Q, Belangero SI, Gadelha A, Bressan RA, Noto C (2019) Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. Eur Neuropsychopharmacol 29:416–431

Article  CAS  PubMed  Google Scholar 

Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ (2018) Tnf-alpha and il-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res 199:281–284

Article  PubMed  PubMed Central  Google Scholar 

Ullah I, Awan HA, Aamir A, Diwan MN, de Filippis R, Awan S, Irfan M, Fornaro M, Ventriglio A, Vellante F, Pettorruso M, Martinotti G, Di Giannantonio M, De Berardis D (2021) Role and perspectives of inflammation and c-reactive protein (crp) in psychosis: an economic and widespread tool for assessing the disease. Int J Mol Sci. https://doi.org/10.3390/ijms222313032

Article  PubMed  PubMed Central  Google Scholar 

Liang W, Greven J, Fragoulis A, Horst K, Blasius F, Wruck C, Pufe T, Kobbe P, Hildebrand F, Lichte P (2022) Sulforaphane-dependent up-regulation of nrf2 activity alleviates both systemic inflammatory response and lung injury after hemorrhagic shock/resuscitation in mice. Shock 57:221–229

Article  CAS  PubMed  Google Scholar 

Li B, Kim DS, Yadav RK, Kim HR, Chae HJ (2015) Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat h9c2 cells. Int J Mol Med 36:53–64

Article  PubMed  PubMed Central  Google Scholar 

Shirai Y, Fujita Y, Hashimoto R, Ohi K, Yamamori H, Yasuda Y, Ishima T, Suganuma H, Ushida Y, Takeda M, Hashimoto K (2015) Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLoS ONE 10:e0127244

Article  PubMed  PubMed Central  Google Scholar 

Hei G, Smith RC, Li R, Ou J, Song X, Zheng Y, He Y, Arriaza J, Fahey JW, Cornblatt B, Kang D, Yang Y, Huang J, Wang X, Cadenhead K, Zhang M, Davis JM, Zhao J, Jin H, Wu R (2022) Sulforaphane effects on cognition and symptoms in first and early episode schizophrenia: a randomized double-blind trial. Schizophrenia Bull Open. https://doi.org/10.1093/schizbullopen/sgac024

Article  Google Scholar 

Dickerson F, Origoni A, Katsafanas E, Squire A, Newman T, Fahey J, Xiao JC, Stallings C, Goga J, Khushalani S, Yolken R (2021) Randomized controlled trial of an adjunctive sulforaphane nutraceutical in schizophrenia. Schizophr Res 231:142–144

Article  CAS  PubMed  Google Scholar 

Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T, Yoshida T, Iyo M, Hashimoto K (2015) An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia. Clin Psychopharmacol Neurosci 13:62–67

Article  CAS  PubMed  PubMed Central